Skip to main content

Table 2 Baseline characteristics and outcome measures after natural dendritic cell vaccination

From: The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

   pDC-MEL1 mDC-MEL1 mDC-PROS2
Cancer type   Melanoma Melanoma Prostate
Patients Male/female 10/5 10/4 12/0
Age, years Median (range) 52 (35–69) 50 (31–73) 69.5 (52–78)
Disease stage M1a 1 4a 2
M1b 8 2 5
M1c 6 9 3
Unknown 0 0 2
Line of systemic treatment 1st line 14 14 0
2nd line or later 1 0 12b
Number of vaccines received 2 or 3 12 9 12
6 2 2
9 1 3
Vaccine-specific toxicity Grade 1 6 4 n.a.
Grade 2 0 1 n.a.
Immunological responses Control antigenc (blood) T-cell: 10/14
Ab: 12/15
T-cell. 11/13
Ab: 4/13
T-cell: n.t.
Ab: 4/12
Control antigen (DTH) n.t. n.t. 4/12d
Tumor antigen (blood) 7/15e 4/12 0/12
Tumor antigen (DTH) 2/15 4/13 0/12d
Progression-free survival Median (range; months) 4.0 (< 4–20) 2.8 (< 4–67+) n.a.
Overall survival Median (range; months) 22.3 (< 4–64) 13.3 (< 4–67+) 18 (6–40+)
  1. aIncluding 1 irresectable stage III melanoma patient
  2. bAll patients received 2–4 lines of hormonal treatment. Four patients received prior chemotherapy
  3. cT-cell proliferation upon stimulation with the control antigen (T-cell) and control antigen-specific antibodies (Ab) are shown
  4. dSkin reaction tested only
  5. eNo tumor-specific T-cells were detected prior to restimulation
  6. Abbreviations: n.a., not available; n.t., not tested